Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: A naturalistic comparative study

Journal of Clinical Psychopharmacology

Volumn 24, Issue 3, 2004, Pages 245-254

  Ritsner, Michael ^a,b   Perelroyzen, Galina ^a   Ilan, Hanan ^a   Gibel, Anatoly ^a  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOTIAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; AWARENESS; CLINICAL PRACTICE; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PARKINSONISM; PATIENT SATISFACTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 2442688064     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000125684.82219.53     Document Type: Article

References (56)

1. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19(3):609-618.
2. Awad AG, VorugantiL NP, Helslegrave RJ, et al. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol. 1996; 11(suppl 2):55-59.
3. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995; 10(suppl 3): 133-138.
4. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-651.
5. Lader M. Some adverse effects of antipsychotics: prevention and treatment. J Clin Psychiatry. 1999;60(suppl 12):18-21.
6. Waserman J, Criollo M. Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatr Serv. 2000;51(5): 666-668.
7. Wallace M. Real progress - the patient's perspective. Int Clin Psychopharmacol. 2001;16(suppl 1):S21-S24.
8. Endicott J, Nee J, Harrison W, et al. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993; 29(2):321-326.
9. Ritsner M, Kurs R. Impact of antipsychotic agents and their side effects on the quality of life in schizophrenia. Exp Rev Pharmacoecon Outcomes Res. 2002;2(4):89-98.
10. Ritsner M, Kurs R. Quality of life outcomes in mental illness: schizophrenia, mood and anxiety disorders. Exp Rev Pharmacoecon Outcomes Res. 2003;3(2):189-199.
11. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
12. Awad AG, Hogan TP, Voruganti LN. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol. 1995;10(suppl 3):123-132.
13. Gervin M, Browne S, Garavan J. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatr. 1999;14(7):405-409.
14. Cabeza IG, Amador MS, Lopez CA, et al. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res. 2000;41(2):349-355.
15. Hofer A, Kemmler G, Eder U, et al. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry. 2002;63(1):49-53.
16. Hellewell JS. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs. 2002;16(7):457-471 [review].
17. Ritsner M, Ponizovsky A, Endicott J, et al. Relatively small impact adverse events of antipsychotics on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol. 2002;12:31-38.
18. Selten JP, Wiersma D, van den Bosch RJ. Distress attributed to negative symptoms in schizophrenia. Schizophr Bull. 2000;26(3):737-744.
19. Freeman D, Garety PA, Kuipers E. Persecutory delusions: developing the understanding of belief maintenance and emotional distress. Psychol Med. 2001;31(7):1293-1306.
20. Ritsner M, Modai I, Ponizovsky A. Assessing psychological distress in psychiatric patients: validation of the Talbieh Brief Distress Inventory. Compr Psychiatry. 2002;43:229-234.
21. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol. 2001; 16(3):153-162.
22. Ritsner M, Modai I, Kurs R, et al. Subjective quality of life measurements in severe mental health patients: measuring quality of life of psychiatric patients: comparison two questionnaires. Qual Life Res. 2002;11:553-561.
23. Ritsner M, Modai I, Endicott J, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry. 2000;61(11):880-889 [quiz 890].
24. Lasalvia A, Ruggeri M, Santolini N. Subjective quality of life: its relationship with clinician-rated and patient-rated psychopathology. The South-Verona Outcome Project 6. Psychother Psychosom. 2002;71(5): 275-284.
25. Amador XA, Strauss DH, Yale SA, et al. Assessment of insight in psychosis. Am J Psychiatry. 1993;150:873-879.
26. Cuffel BJ, Alford J, Fischer EP, et al. Awareness of illness in schizophrenia and outpatient treatment compliance. J Nerv Ment Dis. 1996; 184:653-659.
27. Smith TE, Hull JW, Goodman M, et al. The relative influences of symptoms, insight and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 1999;187: 102-108.
28. Lysaker PH, Bell MD, Bryson GJ, et al. Psychosocial function and insight in schizophrenia. J Nerv Ment Dis. 1998;186:432-436.
29. Francis JL, Penn DL. The relationship between insight and social skill in persons with severe mental illness. J Nerv Ment Dis. 2001;189:822-829.
30. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51:826-836.
31. Schwartz RC. The relationship between insight, illness and treatment outcome in schizophrenia. Psychiatr Q. 1998;69(1):1-22.
32. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10): 892-909.
33. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(12):1121-1128.
34. Ritsner M, Kurs R, Gibel A, et al. Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry. 2003; 64(3):308-315.
35. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry. 1999;60(suppl 23):5-9.
36. Emsley R, Oosthuizen P. The new and evolving pharmacotherapy of schizophrenia. Psychiatr Clin North Am. 2003;26(1):141-163.
37. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Safety. 2000;22(3):195-214.
38. Awad AG, Voruganti LN. Quality of life and new antipsychotics in schizophrenia. Are patients better off? Int J Soc Psychiatry. 1999; 45(4):268-275.
39. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43:135-145.
40. Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002;57(2-3):201-208.
41. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J. 2000;321(7273):1371-1376.
42. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
43. White L, Harvey PD, Opler L, et al. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology. 1997;30(5):263-274.
44. Chouinard G, Ross-Chouinard A, AnnAnnable L. Extrapyramidal symptom rating scale. Can J Neurol Sci. 1980;7:233.
45. Ritsner M, Rabinowitz J, Slyuzberg M. The Talbieh Brief Distress Inventory: a brief instrument to measure psychological distress among immigrants. Compr Psychiatry. 1995;36(6):448-453.
46. Bradshaw W, Brekke JS. Subjective experience in schizophrenia: factors influencing self-esteem, satisfaction with life, and subjective distress. Am J Orthopsychiatry. 1999;69(2):254-260.
47. Horan WP, Blanchard JJ. Emotional responses to psychosocial stress in schizophrenia: the role of individual differences in affective traits and coping. Schizophr Res. 2003;60(2-3):271-283.
48. Amador XF, Strauss DH, Yale SA, et al. Awareness of illness in schizophrenia. Schizophr Bull. 1991;17:113-132.
49. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 3rd ed. 2000 Oslo: WHO Collaborating Centre for Drug Statistics Methodology.
50. Hintze JL. NCSS 6.0. Statistical System for Windows. User's Guide. Kaysville, UT: Number Cruncher Statistical Systems; 1998.
51. Garcia-Cabeza I, Gomez JC, Sacristan JA. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO study). BMC Psychiatry. 2001;1(1):7.
52. Gomez JC, Crawford AM. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. J Clin Psychiatry. 2001;62(suppl 2):6-11.
53. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull. 2002;28(1):43-61.
54. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000;61(suppl 8):5-11 [discussion 12-13].
55. Barnes TRE, Joyce EM. Antipsychotic drug treatment: recent advances. Curr Opin Psychiatry. 2001;14:25-37.
56. Moritz S, Woodward TS, Krausz M, et al. Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. Int Clin Psychopharmacol. 2002;17(1):41-44.